SKIP TO
CONTENT
Philips Recalled CPAP, Bi-Level PAP, and Mechanical...
featured news
April 25, 2014
Healthcare Fraud
Pfizer Unsuccessful in Avoiding Off-Label Marketing False Claims Act Case
In a recent False Claims Act case involving the mental health drug Geodon, Pfizer reportedly lost its bid to have the case dismissed after unsuccessfully arguing, among other claims, that relators failed the “first-to-file” and “public disclosure” requirements contained within the language of the FCA. Specifically, the FCA precludes whistleblowers […]
April 21, 2014
Healthcare Fraud
Detroit-Area Physician Pleads Guilty to Medicare Fraud and Violations of the False Claims Act
When a physician, hospital, or pharmaceutical company engages in fraud against the U.S. government, it is not uncommon for the defendant to face additional penalties and sanctions beyond mere repayment of taxpayer dollars. For example, Medicare fraudsters may face incarceration and probation for engaging in this type of crime – […]
April 15, 2014
Healthcare Fraud
American Family Care Inc. to Pay $1.2 Million to Settle Medicaid and Medicare Fraud Claims
In its latest efforts to combat Medicare fraud, the Department of Justice recently announced a $1.2 million settlement with an Alabama-based walk-in clinic. American Family Care, Inc. has agreed to the settlement after allegations of upcoding and fraudulent invoice practices surfaced when a whistleblower filed a qui tam lawsuit against […]
April 10, 2014
Healthcare Fraud
Repeat Offender Valley Heart Consultants to Pay $3.9 Million to Settle Claims of Medicare Fraud
In a recent press release, the Department of Justice applauds the concerted efforts of the Department of Health and Human Services with the FBI in identifying and investigating allegations of billing fraud spanning nearly six years. According to allegations, Texas-based Valley Heart Consultants was engaging in the practice of performing […]
April 9, 2014
Healthcare Fraud
Arkansas Supreme Court Takes Different View of Risperdal Fraud Case
Late last year, the federal Department of Justice settled a long-running dispute with drug maker Johnson & Johnson over allegations of the off-label marketing of the anti-psychotic drug Risperdal. As is often the case, Johnson & Johnson also faced several state False Claims Act and Deceptive Trade Practices Act allegations, […]
schedule a free consultation
"*" indicates required fields
By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.
$50B+
in Settlements & Verdicts
53+
Years of High-Profile Cases
100+
Attorneys Protecting Your Rights
2X
Named “Trial Lawyer of the Year”
50
States in Which The Firm Has Successfully Litigated Cases
On the Cutting Edge of the Profession
Legal Intelligencer
53
Years
